{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:57:23Z","timestamp":1774288643886,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12185-022-03524-4","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T13:03:01Z","timestamp":1672146181000},"page":"492-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Moving towards biologically informed treatment strategies for T-cell lymphomas"],"prefix":"10.1007","volume":"117","author":[{"given":"Robert","family":"Stuver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"3524_CR1","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720\u20131748.","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"11","key":"3524_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229\u201353.","journal-title":"Blood"},{"issue":"10","key":"3524_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u201375.","journal-title":"Ann Oncol"},{"issue":"25","key":"3524_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3524_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137.","journal-title":"Ann Oncol"},{"issue":"18","key":"3524_CR6","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"3","key":"3524_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626\u201333.","journal-title":"Blood"},{"issue":"12","key":"3524_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","volume":"102","author":"Y Maeda","year":"2017","unstructured":"Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097\u2013103.","journal-title":"Haematologica"},{"issue":"9","key":"3524_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink M, Meeuwes FO, van der Poel MWM, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140(9):1009\u201319.","journal-title":"Blood"},{"issue":"9","key":"3524_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"S Park","year":"2019","unstructured":"Park S, Horwitz S, Foss F, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507\u201317.","journal-title":"Cancer"},{"issue":"19","key":"3524_CR11","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","volume":"6","author":"KJ Savage","year":"2022","unstructured":"Savage KJ, Horwitz SM, Advani R, et al. Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2. Blood Adv. 2022;6(19):5550\u20135.","journal-title":"Blood Adv"},{"key":"3524_CR12","unstructured":"Horwitz SM, Ansell S, Ai WZ, et al. T-Cell Lymphomas, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2022) 20(3):285\u2013308."},{"key":"3524_CR13","first-page":"v108","volume":"26","author":"F D\u2019amore","year":"2015","unstructured":"D\u2019amore F, Gaulard P, Tr\u00fcmper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up \u2020. ESMO Updated Clinical Practice Guidelines. 2015;26:v108\u201315.","journal-title":"ESMO Updated Clinical Practice Guidelines"},{"issue":"3","key":"3524_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bjh.17951","volume":"196","author":"CP Fox","year":"2022","unstructured":"Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196(3):507\u201322.","journal-title":"Br J Haematol"},{"issue":"15","key":"3524_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376.","journal-title":"Blood"},{"issue":"9","key":"3524_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"12","key":"3524_CR17","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33(12):2867\u201383.","journal-title":"Leukemia"},{"key":"3524_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-99716-2_2","volume":"176","author":"J Iqbal","year":"2019","unstructured":"Iqbal J, Amador C, McKeithan TW, Chan WC. Molecular and genomic landscape of peripheral T-cell lymphoma. Cancer Treat Res. 2019;176:31\u201368.","journal-title":"Cancer Treat Res"},{"issue":"10168","key":"3524_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"issue":"3","key":"3524_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398.","journal-title":"Ann Oncol"},{"issue":"9467","key":"3524_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S0140-6736(05)61026-4","volume":"365","author":"J Cuzick","year":"2005","unstructured":"Cuzick J. Forest plots and the interpretation of subgroups. The Lancet. 2005;365(9467):1308.","journal-title":"The Lancet"},{"issue":"9","key":"3524_CR22","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603\u2013e603.","journal-title":"Blood Cancer J"},{"key":"3524_CR23","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1158\/1538-7445.AM2015-2469","volume":"75","author":"SJ Gardai","year":"2015","unstructured":"Gardai SJ, Epp A, Law C-L. Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death. Cancer Res. 2015;75:2469\u20132469.","journal-title":"Cancer Res"},{"issue":"13","key":"3524_CR24","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","volume":"110","author":"E Oflazoglu","year":"2007","unstructured":"Oflazoglu E, Stone IJ, Gordon KA, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood. 2007;110(13):4370\u20132.","journal-title":"Blood"},{"issue":"8","key":"3524_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"3524_CR26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","volume":"27","author":"D Jagadeesh","year":"2022","unstructured":"Jagadeesh D, Horwitz S, Bartlett NL, et al. Response to Brentuximab Vedotin by CD30 expression in non-Hodgkin lymphoma. Oncologist. 2022;27(10):864\u201373.","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"3524_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2021-148102","volume":"138","author":"NS Grover","year":"2021","unstructured":"Grover NS, Ivanova A, Moore DT, et al. CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory Hodgkin lymphoma and CD30+ cutaneous T cell lymphoma. Blood. 2021;138(Supplement 1):742\u2013742.","journal-title":"Blood"},{"key":"3524_CR28","doi-asserted-by":"crossref","unstructured":"Ahmed S, Flinn IW, Mei M, et al. Safety and efficacy profile of autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT Trial). Blood. (2021) 138:3847\u20133847.","DOI":"10.1182\/blood-2021-146100"},{"issue":"19","key":"3524_CR29","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323.","journal-title":"Blood"},{"issue":"11","key":"3524_CR30","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280\u20139.","journal-title":"Blood"},{"issue":"1","key":"3524_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2014.261","volume":"29","author":"JH Schatz","year":"2015","unstructured":"Schatz JH, Horwitz SM, Teruya-Feldstein J, et al. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2015;29(1):237\u201341.","journal-title":"Leukemia"},{"issue":"11","key":"3524_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141906","volume":"10","author":"HM Simpson","year":"2015","unstructured":"Simpson HM, Khan RZ, Song C, et al. Concurrent mutations in ATM and genes associated with common \u03b3 chain signaling in peripheral T cell lymphoma. PLoS ONE. 2015;10(11): e0141906.","journal-title":"PLoS ONE"},{"key":"3524_CR33","first-page":"3409","volume":"79","author":"RN Ptashkin","year":"2019","unstructured":"Ptashkin RN, Benayed R, Ziegler J, et al. Abstract 3409: MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies. Mol Cell Biol\/Gen. 2019;79:3409\u20133409.","journal-title":"Mol Cell Biol\/Gen."},{"issue":"Supplement 1","key":"3524_CR34","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2021-151779","volume":"138","author":"WT Johnson","year":"2021","unstructured":"Johnson WT, Ganesan N, Epstein-Peterson ZD, et al. TP53 Mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy. Blood. 2021;138(Supplement 1):1367\u20131367.","journal-title":"Blood"},{"issue":"11","key":"3524_CR35","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952\u201363.","journal-title":"Blood"},{"issue":"4","key":"3524_CR36","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148\u201351.","journal-title":"Haematologica"},{"issue":"2","key":"3524_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"15","key":"3524_CR38","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741\u201352.","journal-title":"Blood"},{"issue":"2","key":"3524_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370.","journal-title":"Nat Genet"},{"issue":"2","key":"3524_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259-273.e7.","journal-title":"Cancer Cell"},{"issue":"19","key":"3524_CR41","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4(19):4640\u20137.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"3524_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2021-145495","volume":"138","author":"J Ruan","year":"2021","unstructured":"Ruan J, Moskowitz AJ, Mehta-Shah N, et al. High rates of remission with the initial treatment of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL): Clinical outcomes and biomarker analysis of a multi-center phase II study. Blood. 2021;138(Supplement 1):138\u2013138.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3524_CR43","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2021-146100","volume":"138","author":"S Horwitz","year":"2021","unstructured":"Horwitz S, Nikitina A, Kotlov N, et al. The combination of Duvelisib and Romidepsin (DR) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results and biomarker analysis. Blood. 2021;138(Supplement 1):3847\u20133847.","journal-title":"Blood"},{"issue":"10","key":"3524_CR44","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ajh.26288","volume":"96","author":"N Mehta-Shah","year":"2021","unstructured":"Mehta-Shah N, Lunning MA, Moskowitz AJ, et al. Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. Am J Hematol. 2021;96(10):1211\u201322.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"3524_CR45","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2021-145851","volume":"138","author":"SP Iyer","year":"2021","unstructured":"Iyer SP, Huen A, Ai WZ, et al. Safety and efficacy of Tenalisib given in combination with Romidepsin in patients with relapsed\/refractory T-cell lymphoma: final rResults from a phase I\/II open label multi-center study. Blood. 2021;138(Supplement 1):1365\u20131365.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3524_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-143252","volume":"136","author":"SP Iyer","year":"2020","unstructured":"Iyer SP, Xu J, Becnel MR, et al. A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL). Blood. 2020;136(Supplement 1):40\u20131.","journal-title":"Blood"},{"issue":"8","key":"3524_CR47","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398.","journal-title":"Blood"},{"key":"3524_CR48","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood-2019-121401","volume":"134","author":"SM Horwitz","year":"2019","unstructured":"Horwitz SM, Mehta-Shah N, Pro B, et al. Dose otimization of duvelisib in patients with relapsed or refractory peripheral T-Cell lymphoma from the phase 2 primo trial: Selection of regimen for the dose-expansion phase. Blood. 2019;134:1567\u20131567.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3524_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2020-140412","volume":"136","author":"B Pro","year":"2020","unstructured":"Pro B, Brammer JE, Casulo C, et al. Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: dose optimization efficacy update and expansion phase initial results. Blood. 2020;136(Supplement 1):38\u20139.","journal-title":"Blood"},{"key":"3524_CR50","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2021-148939","volume":"138","author":"JE Brammer","year":"2021","unstructured":"Brammer JE, Zinzani PL, Zain J, et al. Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis. Blood. 2021;138:2456.","journal-title":"Blood"},{"key":"3524_CR51","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/01.HS9.0000847552.42271.7c","volume":"6","author":"PL Zinzani","year":"2022","unstructured":"Zinzani PL, Zain J, Mead M, et al. P1172: Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: updated expansion phase analysis. Hemasphere. 2022;6:1058\u20139.","journal-title":"Hemasphere"},{"issue":"8","key":"3524_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082293","volume":"12","author":"A Huen","year":"2020","unstructured":"Huen A, Haverkos BM, Zain J, et al. Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with aelapsed\/refractory T-cell lymphoma. Cancers (Basel). 2020;12(8):1\u201314.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3524_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"3524_CR54","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","volume":"131","author":"JS van Arnam","year":"2018","unstructured":"van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131(21):2320\u201330.","journal-title":"Blood"},{"issue":"26","key":"3524_CR55","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"issue":"11","key":"3524_CR56","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2013.104","volume":"27","author":"R Ohgami","year":"2013","unstructured":"Ohgami R, Ma L, Merker J, et al. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013;27(11):2244\u20137.","journal-title":"Leukemia"},{"key":"3524_CR57","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1200\/JCO.2022.40.16_suppl.7563","volume":"40","author":"WS Kim","year":"2022","unstructured":"Kim WS, Yoon DH, Song Y, et al. A phase I\/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma. J Clin Oncol. 2022;40:7563\u20137563. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7563.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3524_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/asheducation-2018.1.63","volume":"2018","author":"ED Jacobsen","year":"2018","unstructured":"Jacobsen ED, Weinstock DM. Challenges and implications of genomics for T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2018;2018(1):63\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"3524_CR59","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","volume":"128","author":"RL Boddicker","year":"2016","unstructured":"Boddicker RL, Razidlo GL, Dasari S, et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood. 2016;128(9):1234\u201345.","journal-title":"Blood"},{"issue":"1","key":"3524_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053767","volume":"8","author":"S Ehrentraut","year":"2013","unstructured":"Ehrentraut S, Nagel S, Scherr ME, et al. t(8;9)(p22;p24)\/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. PLoS ONE. 2013;8(1): e53767.","journal-title":"PLoS ONE"},{"issue":"4","key":"3524_CR61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516\u201332.","journal-title":"Cancer Cell"},{"issue":"25","key":"3524_CR62","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2014-07-588434","volume":"124","author":"T Velusamy","year":"2014","unstructured":"Velusamy T, Kiel MJ, Sahasrabuddhe AA, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood. 2014;124(25):3768\u201371.","journal-title":"Blood"},{"issue":"7","key":"3524_CR63","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","volume":"120","author":"E Lierman","year":"2012","unstructured":"Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2\u2013positive chronic eosinophilic leukemia. Blood. 2012;120(7):1529\u201331.","journal-title":"Blood"},{"issue":"8","key":"3524_CR64","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901\u20133.","journal-title":"Blood"},{"issue":"7","key":"3524_CR65","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","volume":"132","author":"Y Sakamoto","year":"2018","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758\u201361.","journal-title":"Blood"},{"issue":"5","key":"3524_CR66","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/hon.3072","volume":"40","author":"Y Sakamoto","year":"2022","unstructured":"Sakamoto Y, Ishida T, Masaki A, et al. CCR7 alterations associated with inferior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Hematol Oncol. 2022;40(5):876\u201384.","journal-title":"Hematol Oncol"},{"issue":"10","key":"3524_CR67","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","volume":"107","author":"N Tanaka","year":"2022","unstructured":"Tanaka N, Mori S, Kiyotani K, et al. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma. Haematologica. 2022;107(10):2418\u201331.","journal-title":"Haematologica"},{"issue":"26","key":"3524_CR68","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1182\/blood.2021014468","volume":"139","author":"S Beygi","year":"2022","unstructured":"Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732\u20136.","journal-title":"Blood"},{"key":"3524_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","volume":"6","author":"SP Iyer","year":"2022","unstructured":"Iyer SP, Sica RA, Ho PJ, et al. S262: The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9-engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies. Hemasphere. 2022;6:163\u20134.","journal-title":"Hemasphere"},{"issue":"3","key":"3524_CR70","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","volume":"5","author":"S Beygi","year":"2021","unstructured":"Beygi S, Fernandez-Pol S, Duran G, et al. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv. 2021;5(3):771\u20134.","journal-title":"Blood Adv"},{"issue":"12","key":"3524_CR71","doi-asserted-by":"publisher","first-page":"E319","DOI":"10.1002\/ajh.25967","volume":"95","author":"E Bossi","year":"2020","unstructured":"Bossi E, Aroldi A, Brioschi FA, et al. Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy. Am J Hematol. 2020;95(12):E319\u201321.","journal-title":"Am J Hematol"},{"issue":"12","key":"3524_CR72","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","volume":"111","author":"R Fukano","year":"2020","unstructured":"Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540\u20137.","journal-title":"Cancer Sci"},{"issue":"1","key":"3524_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","volume":"13","author":"E Mulvey","year":"2020","unstructured":"Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020;13(1):59.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3524_CR74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.seminhematol.2021.02.004","volume":"58","author":"ZD Epstein-Peterson","year":"2021","unstructured":"Epstein-Peterson ZD, Horwitz SM. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas. Semin Hematol. 2021;58(2):78\u201384.","journal-title":"Semin Hematol"},{"issue":"6","key":"3524_CR75","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1586\/17512433.2015.1088382","volume":"8","author":"KS Panageas","year":"2015","unstructured":"Panageas KS. Clinical trial design for rare cancers - why a less conventional route may be required. Expert Rev Clin Pharmacol. 2015;8(6):661.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"3524_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43586-022-00100-2","volume":"2","author":"C Pizzamiglio","year":"2022","unstructured":"Pizzamiglio C, Vernon HJ, Hanna MG, Pitceathly RDS. Designing clinical trials for rare diseases: unique challenges and opportunities. Nature Reviews Methods Primers. 2022;2(1):1\u20132.","journal-title":"Nature Reviews Methods Primers"},{"issue":"Supplement 1","key":"3524_CR77","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","volume":"132","author":"F d\u2019Amore","year":"2018","unstructured":"d\u2019Amore F, Lepp\u00e4 S, da Silva MG, et al. Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-Cell lymphoma treated with CHOP chemotherapy with or without Alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132(Supplement 1):998\u2013998.","journal-title":"Blood"},{"issue":"1","key":"3524_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","volume":"35","author":"GG Wulf","year":"2021","unstructured":"Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial. Leukemia. 2021;35(1):143\u201355.","journal-title":"Leukemia"},{"issue":"3","key":"3524_CR79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP Versus vHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"3524_CR80","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1182\/blood-2018-99-119763","volume":"132","author":"A Chiappella","year":"2018","unstructured":"Chiappella A, Carniti C, Evangelista A, et al. Romidepsin-CHOEP plus intensification with up-front stem-cell transplantation in peripheral T-Cell lymphoma: final results of phase Ib PTCL13 study of the fondazione Italiana Linfomi. Blood. 2018;132(Supplement 1):2902\u20132902.","journal-title":"Blood"},{"issue":"1","key":"3524_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","volume":"10","author":"PB Johnston","year":"2021","unstructured":"Johnston PB, Cashen AF, Nikolinakos PG, et al. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Exp Hematol Oncol. 2021;10(1):15.","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"3524_CR82","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood.V130.Suppl_1.818.818","volume":"130","author":"A Shustov","year":"2017","unstructured":"Shustov A, Johnston PB, Barta SK, et al. Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma (PTCL): A phase 1 dose-escalation study. Blood. 2017;130(Supplement 1):818\u2013818.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3524_CR83","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2021-151105","volume":"138","author":"AF Herrera","year":"2021","unstructured":"Herrera AF, Zain J, Savage KJ, et al. Brentuximab Vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-Cell lymphomas. Blood. 2021;138(Supplement 1):133\u2013133.","journal-title":"Blood"},{"issue":"3","key":"3524_CR84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1200\/JCO.21.02463","volume":"40","author":"AJ Moskowitz","year":"2022","unstructured":"Moskowitz AJ. Moving beyond one size fits all for T-cell lymphoma. J Clin Oncol. 2022;40(3):221\u20134.","journal-title":"J Clin Oncol"},{"issue":"17","key":"3524_CR85","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","volume":"2","author":"T Sugio","year":"2018","unstructured":"Sugio T, Miyawaki K, Kato K, et al. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv. 2018;2(17):2242.","journal-title":"Blood Adv"},{"issue":"16","key":"3524_CR86","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370.","journal-title":"Blood"},{"key":"3524_CR87","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/blood.V130.Suppl_1.819.819","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Koch R, Mehta-Shah N, et al. In Vitro, In Vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, in combination with romidepsin or Bortezomib in relapsed\/refractory T-cell lymphoma. Blood. 2017;130:819\u2013819.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3524_CR88","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","volume":"132","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Moskowitz AJ, Jacobsen ED, et al. The combination of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts. Blood. 2018;132(Supplement 1):683\u2013683.","journal-title":"Blood"},{"issue":"18","key":"3524_CR89","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","volume":"21","author":"KM Zullo","year":"2015","unstructured":"Zullo KM, Guo Y, Cooke L, et al. Aurora a kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015;21(18):4097\u2013109.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3524_CR90","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1182\/blood.V124.21.1744.1744","volume":"124","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas. Blood. 2014;124(21):1744.","journal-title":"Blood"},{"issue":"9","key":"3524_CR91","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","volume":"21","author":"S Jain","year":"2015","unstructured":"Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell Lymphoma. Clin Cancer Res. 2015;21(9):2096\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3524_CR92","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","volume":"118","author":"M Kalac","year":"2011","unstructured":"Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506\u201316.","journal-title":"Blood"},{"issue":"17","key":"3524_CR93","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1182\/blood.2019002806","volume":"134","author":"DM Weinstock","year":"2019","unstructured":"Weinstock DM, Horwitz SM. TFH lymphomas: the times they aza-changin\u2019? Blood. 2019;134(17):1364\u20135.","journal-title":"Blood"},{"issue":"7","key":"3524_CR94","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or snergy. Cell. 2017;171(7):1678-1691.e13.","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1007\/s12185-023-03565-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03524-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:53:33Z","timestamp":1680170013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03524-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3524"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03524-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-023-03565-3","URL":"https:\/\/doi.org\/10.1007\/s12185-023-03565-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}